Use of Checkpoint Inhibitors in Urothelial Carcinoma
Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors in the treatment of urothelial carcinoma.
Bladder Cancer
Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer
Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.
Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
Clinical trials show pembrolizumab active against mucosal melanoma, extends survival in bladder cancer.
Nivolumab Approved for Locally Advanced or Metastatic Bladder Cancer
The US Food and Drug Administration has approved nivolumab (Opdivo) for the treatment of patients with locally advanced or metastatic bladder cancer.
How We Developed a New Protocol for Treatment of Urethral Carcinoma
Faced with a harsh treatment option, a patient with genitourinary cancer helps create a treatment plan that preserves his self-image.
Smoking-related Cancer Deaths Highest in Southern United States
Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.
New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
A recent study undertaken sought to examine the effects of chemotherapy on bladder cancer cells and possible connections to later treatment resistance.
Nivolumab Monotherapy Active in Recurrent Metastatic Urothelial Carcinoma
Single-agent nivolumab induced durable clinical responses with a manageable safety profile in previously treated patients with locally advanced or metastatic urothelial carcinoma.
Mycobacteria Treatment for Bladder Cancer More Effective With Emulsification in Olive Oil
Emulsifying Mycobacterium brumae in olive oil appeared promising for producing a robust immune response in preclinical tests. Recent research has indicated that M brumae is a safer alternative to BCG.
Atezolizumab Approved for Locally Advanced or Metastatic Urothelial Carcinoma
US FDA granted accelerated approval to atezolizumab (TECENTRIQ), indicated for the treatment of locally advanced or metastatic UC in patients whose disease progressed during or following platinum-based chemotherapy, or in the neoadjuvant or adjuvant setting.
